Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

Branaplam, an mRNA splicing modifier, joins the many unsuccessful agents for Huntington disease as biopharma continues to be challenged with trial holds and failures.

Novartis Discontinues Huntington Disease Program Following Phase 2b Study 

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2023 that neurology health care professionals should keep their eyes on.

5 Clinical Trial Readouts in Neurology to Look for in 2023

Donald Whiting, MD, chair of Allegheny Health Network’s Neurosciences Institute, provided insight on ADvance II, a multinational trial exploring the use of deep brain stimulation in patients with mild Alzheimer disease. 

Using Deep Brain Stimulation to Treat Alzheimer Disease Symptoms

Videos

The psychologist and professor in the department of rehabilitation medicine at the University of Washington shared her perspective on the state of mental health care in multiple sclerosis. [WATCH TIME: 4 minutes]  

State of Mental Health Care for Patients With MS: Dawn Edhe, PhD

, has been with the team since October 2019. Follow him on Twitter 

Psychologist and professor in the department of rehabilitation medicine at the University of Washington

The executive direct of Cure CMD discussed the state of care for patients with congenital muscular dystrophies, the need for new treatments, and the patience with gene therapies.

NeuroVoices: Rachel Alvarez on Identifying Key Treatment Needs for Congenital Muscular Dystrophies

In addition to showing a tolerable safety profile, EQU-001 resulted in reduced IL-17 and IL-1b plasma levels relative to baseline and limited the ability of peripheral mononuclear cells to secrete additional pro-inflammatory cytokines.

Antiseizure Agent EQU-001 Shows Safety, Tolerability, and Preliminary Efficacy in Phase 2 Study

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

NMOSD

Narcolepsy

Parkinson Disease

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

 video series brings together pairs of expert clinicians and physicians to discuss the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

1rem

David Dodick, MD, and Robert Cowan, MD, FAAN, review changes to the treatment landscape for acute migraine. 

The Changing Treatment Landscape for Acute Migraine

Burden of Migraine

 Advances in the Treatment of Acute Migraine

Gepants for Acute Migraine: Safety & Efficacy Data

Gepants for Acute Migraine: Patient Management

Real-World Experience With Gepants for Acute Migraine

Acute Migraine Treatment: What’s Next?

Treating Acute Migraine in the Community Setting

Treatment Goals for Acute Migraine

Acute Migraine Treatment Goals

Patient Selection for Acute Migraine Therapy

Rimegepant: Treatment for Acute Migraine

Ubrogepant: Treatment for Acute Migraine

Therapies in Development for Acute Migraine